GlassScriptPhysician profile
Jason A Dunn
NPI 1346538154
$7,829.59
in general payments reported to CMS, 2019-2025
26 companies · $1,167 in 2025
The $1,167 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,662 · 2020: $355 · 2021: $592 · 2022: $891 · 2023: $768 · 2024: $1,394 · 2025: $1,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,311 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,310.90 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,606.67 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $1,122.74 | 2022-2025 | Infuse, Biotrue, Vyzulta |
| Alcon Vision LLC | $605.86 | 2019-2025 | Eysuvis, Rocklatan, Tryptyr |
| Novartis Pharmaceuticals Corporation | $592.93 | 2019-2023 | |
| Coopervision INC. | $348.03 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Mallinckrodt Hospital Products INC. | $333.23 | 2021-2025 | Acthar |
| Abbvie INC. | $312.59 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Oyster Point Pharma, INC. | $303.24 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Harrow Eye, LLC | $296.41 | 2024-2025 | Vevye |
| Allergan, INC. | $278.60 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $134.25 | 2025 | Xdemvy |
| Glaukos Corporation | $124.81 | 2022-2024 | Ce-Marked Kxla System, Istent Trabecular Micro-Bypass System Model Is3 |
| Sun Pharmaceutical Industries INC. | $117.40 | 2019-2025 | |
| Lkc Technologies, INC. | $105.90 | 2025 | |
| Apellis Pharmaceuticals, INC. | $76.88 | 2023-2025 | Syfovre |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $64.42 | 2024-2025 | Izervay |
| Thea Pharma INC. | $62.39 | 2024-2025 | Iyuzeh |
| Amgen INC. | $59.99 | 2024-2025 | Tepezza |
| Kala Pharmaceuticals, INC. | $59.97 | 2020-2022 | |
| Johnson & Johnson Vision Care, INC. | $54.48 | 2019-2022 | |
| Dompe US, INC. | $47.49 | 2024 | Oxervate |
| Regeneron Healthcare Solutions, INC. | $35.91 | 2024-2025 | Eylea Hd |
| Aerie Pharmaceuticals, INC. | $24.99 | 2020-2021 | |
| Shire North American Group INC | $23.81 | 2019 | |
| Quidel Corporation | $19.93 | 2019 | |
| Genentech USA, INC. | $16.67 | 2023 | Vabysmo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.